PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" – Trademark Portfolio
Entity Type: 99
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include DARNITSA and DARNITSA GROUP.
13 Boryspilska Street
Kyiv 02093
Showing of trademarks Trademarks
Trademark Classifications
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA"'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" have?
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" file in?
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA"'s most well-known trademarks?
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA"'s registered trademark portfolio includes well-known marks such as DARNITSA and DARNITSA GROUP. These are among 2 currently registered trademarks in the portfolio.
What is PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA"'s trademark registration success rate?
PRIVATE JOINT STOCK COMPANY PHARMACEUTICAL FIRM "DARNITSA" has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.